文献速递膀胱癌与上尿路尿路上皮癌

欧洲泌尿外科协会定义的特高风险非肌层浸润性膀胱癌患者接受卡介苗或早期根治性膀胱切除术后的肿瘤学结局

Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy.
PubMed 文献 · Eur Urol Oncol · 2023-08-08

该研究基于2000至2020年机构NMIBC登记数据库,纳入235例EAU标准特高风险NMIBC患者,其中157例(67%)接受BCG治疗、78例(33%)接受早期RC。中位随访52.8个月,两组总生存率与癌症特异性死亡率均无显著差异(OS p=0.6,CSM p=0.8)。作者认为对部分特高风险NMIBC患者,膀胱内BCG可作为早期RC的合理替代方案。

要点

  • 235例特高风险NMIBC中157例(67%)接受BCG、78例(33%)接受早期RC,中位随访52.8个月。
  • BCG组与早期RC组OS率分别为80.2%与88.1%(p=0.6),CSM率分别为5.3%与4.9%(p=0.8),均无显著差异。
  • BCG组5年高级别复发率和进展率分别为41.9%和17.4%,39例(25%)在BCG后接受延迟RC。

核心结论

  • 研究结果表明,对部分特高风险NMIBC患者,膀胱内BCG可作为早期根治性膀胱切除术的合理替代方案提供。

研究设计与样本

  • 研究为基于本机构NMIBC登记数据库的队列分析,纳入2000至2020年诊断的235例EAU标准特高风险NMIBC患者。

主要发现

  • 235例患者中157例(67%)接受BCG治疗,78例(33%)接受早期RC,中位随访52.8个月。
  • BCG组OS率80.2%、CSM率5.3%,早期RC组OS率88.1%、CSM率4.9%,两组OS(p=0.6)与CSM(p=0.8)均无显著差异。
  • BCG治疗患者5年高级别复发率为41.9%、进展率为17.4%,39例(25%)在BCG后接受延迟RC。
  • 延迟RC(BCG后)与早期RC患者的CSM比较无显著差异(p=0.86)。

关键数值与推荐

  • EAU指南推荐对特高风险NMIBC患者行立即根治性膀胱切除术(early RC),BCG仅推荐用于拒绝或不适合RC的患者。

临床怎么用

  • 作者认为,对部分特高风险NMIBC患者,膀胱内BCG可作为早期RC的合理替代方案提供。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: European Urology Association (EAU) guidelines recommend immediate radical cystectomy (early RC) for patients with very high-risk (VHR) non-muscle invasive bladder cancer (NMIBC), with bacillus Calmette-Guérin (BCG) recommended only for those who refuse or are unfit for RC. OBJECTIVE: To describe oncological outcomes following BCG or early RC in a contemporary cohort of patients with VHR NMIBC (EAU criteria). DESIGN, SETTING, AND PARTICIPANTS: Patients diagnosed with VHR NMIBC between 2000 and 2020 were identified from our institutional NMIBC registry. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcomes were overall survival (OS) and cancer-specific mortality (CSM). Secondary outcomes were the progression rate and high-grade recurrence (HGR) rate for patients receiving BCG. RESULTS AND LIMITATIONS: We identified 235 patients with VHR NMIBC, of whom 157 (67%) received BCG and 78 (33%) underwent early RC. The median follow-up was 52.8 mo. OS and CSM rates were 80.2% and 5.3% in the BCG group, and 88.1% and 4.9% in the early RC group, respectively with no significant difference in OS (p = 0.6) or CSM (p = 0.8) between the two groups. Among the patients treated with BCG, 5-yr HGR and progression rates were 41.9% and 17.4%, respectively; 39 patients (25%) underwent delayed RC after BCG. No significant difference in CSM emerged when comparing patients treated with delayed RC (after BCG) with those undergoing early RC (p = 0.86). CONCLUSIONS: Our findings suggest that intravesical BCG can be offered to patients as a resonable alternative to early RC for selected patients with VHR NMIBC. PATIENT SUMMARY: We evaluated outcomes for patients with very high-risk non-muscle-invasive bladder cancer (NMIBC) treated with BCG (bacillus Calmette-Guérin) versus early surgical removal of the bladder and found no differences in survival. We conclude that BCG could be offered to selected patients with this type of bladder cancer as a reasonable alternative to early bladder removal.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Contieri R, Hensley PJ, Tan WS, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023. PMID: 37558542. doi:10.1016/j.euo.2023.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。